Investigational drug · Phase 3
ELVN-001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive, Chronic Phase Chronic Myeloid Leukemia, BCR::ABL1 Positive CML.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "ELVN-001"
First trial start
2026
Dec 31, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ELVN-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Myeloid Leukemia (CML)
- Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
- Chronic Phase Chronic Myeloid Leukemia, BCR::ABL1 Positive CML
Approved drugs for the same conditions: Chronic myeloid leukemia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "ELVN-001" as an intervention, largest first.
- A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIsPivotal-lookingRecruiting
Enliven TherapeuticsIndustry
NCT07905183 · 450 participants (planned) · Start Dec 31, 2026 · Primary completion Dec 31, 2028
Drug: ELVN-001; TKI · For: Chronic Myeloid Leukemia (CML); Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive; Chronic Phase Chronic Myeloid Leukemia, BCR::ABL1 Positive CML
Sites: Atlanta, Georgia; Indianapolis, Indiana; Morristown, New Jersey · 4 sites in all
Enliven TherapeuticsIndustry
NCT05304377 · 250 participants (planned) · Start May 22, 2022 · Primary completion Dec 2027
Drug: ELVN-001 · For: Chronic Myeloid Leukemia; Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive; Cml
Sites: New York, New York; The Bronx, New York; Portland, Oregon · 45 sites in all
Enliven TherapeuticsIndustry
NCT06787144 · 21 participants (planned) · Start Jan 23, 2025 · Primary completion Jan 2028
Drug: ELVN-001 · For: CML (Chronic Myelogenous Leukemia); Chronic Phase CML
Sites: Akita, Japan; Sapporo, Japan; Suita-shi, Japan · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Relcobatinib, a highly selective ATP-competitive ABL1 tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Gross SD, Eide CA, Burkard MR, et al. · Leukemia 2026
- Emerging BCR::ABL1 inhibitors in chronic myeloid leukemia: current advances and future directions.
Motomura Y, Sasaki K · Int J Hematol 2026
- Chronic myeloid leukemia: incorporation of recent advances into current treatment algorithms.
Haddad FG, Kantarjian H · Blood Cancer J 2026
- Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.
Naderi Z, Sadras T, Branford S, et al. · Curr Hematol Malig Rep 2026
- Management of chronic myeloid leukemia in 2025.
Kantarjian H, Breccia M, Haddad FG, et al. · Cancer 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.